Efficacy and safety of biological therapy in patients with psoriasis and recent neoplasia: experience in real single-center clinical practice

Arch Dermatol Res. 2023 May;315(4):1045-1048. doi: 10.1007/s00403-022-02443-y. Epub 2022 Oct 31.

Authors

Juan Ortiz Álvarez¹, Lourdes Rodríguez Fernández-Freire², Juan Carlos Hernández-Rodríguez², Román Barabash-Neila², Antonio José Durán-Romero², Mercedes Morillo-Andújar², Julián Conejo-Mir Sánchez^{2

3}

Affiliations

¹ Department of Dermatology, Virgen del Rocío University Hospital, Avda Manuel Siurot Sn, 41013, Seville, Spain. juan.ortiz.alvarez94@gmail.com.
² Department of Dermatology, Virgen del Rocío University Hospital, Avda Manuel Siurot Sn, 41013, Seville, Spain.
³ Department of Medicine, University of Seville, Seville, Spain.

PMID: 36316510
DOI: 10.1007/s00403-022-02443-y

No abstract available

Keywords: Biological therapy; Malignancy; Psoriasis.

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Biological Therapy / adverse effects
Humans
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized